“全球创新体系中的关键一环”——访阿斯利康全球首席执行官苏博科（见证·中国机遇）

Core Insights - AstraZeneca views China as a crucial market and a key part of its global innovation system, planning to enhance local R&D, manufacturing, and global exports [2] - The company announced its largest investment plan in China, committing over 100 billion RMB by 2030 to expand R&D centers and production bases [2] - AstraZeneca has established a strong presence in China since 1993, introducing over 40 innovative drugs and exporting products to over 70 countries [3] Investment and Development - The investment will focus on building R&D centers, upgrading production facilities, and supporting the UK-China health innovation ecosystem [2] - The company aims to achieve carbon neutrality in core operations by 2030 and net-zero emissions across the entire value chain by 2045 [4] - AstraZeneca has established two global strategic R&D centers in Beijing and Shanghai, with plans to deepen its R&D presence in China [4] Collaboration and Innovation - The company has formed partnerships with various Chinese biotech firms, research institutions, and universities, leading to fruitful collaborations in clinical trials and artificial intelligence [4] - AstraZeneca recognizes the potential for collaboration between the UK and China in areas such as green transition, artificial intelligence, and life sciences [5] - The company emphasizes the importance of a favorable business environment in China, citing improvements in clinical trial processes and intellectual property protection [3]